SPRB — SPRUCE BIOSCIENCES, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1683553 ·
Last close
$40.49
Market Cap
$116.37M
52W High
$127.90
52W Low
$38.06
ADV30
77,941
Next earnings
—
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -23,981,000 -24,006,000 91,948,000 87,691,000 25,653,000
Jun 2026 0 — -16,512,000 -16,229,000 102,852,000 96,295,000 19,122,000
Mar 2026 0 — -11,987,000 -12,266,000 56,166,000 54,080,000 21,518,000
Dec 2025 0 — -11,100,000 -14,646,000 53,021,000 48,906,000 10,505,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-51,068,000
Investing CF
$-145,000
Financing CF
$128,236,000
CapEx
$-145,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-38.71
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-341,735,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-64,169,000
Pretax Income TTM
$-67,147,000
Interest Exp TTM
$2,978,000
Analysts
9

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -36,513,000 -38,966,000 53,021,000 10,505,000 42,516,000 -33,327,000
Dec 2024 4,911,000 -56,151,000 -53,036,000 45,209,000 16,388,000 28,821,000 -55,964,000
Dec 2023 10,089,000 -51,993,000 -47,919,000 103,946,000 27,437,000 76,509,000 -33,275,000
Dec 2022 0 -47,283,000 -46,180,000 85,648,000 17,162,000 68,486,000 -41,683,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-51,353,000
OpCashFlow TTM
—
Assets (Latest)
$102,852,000
Forward EPS
$4.49

Peers — same industry

TickerNameMarket CapLastDaily %
UPB Upstream Bio, Inc. $115.10M $2.10 —
SCNX Scienture Holdings, Inc. $113.34M $2.76 —
AKBA Akebia Therapeutics, Inc. $111.18M $0.40 —
FHTX Foghorn Therapeutics Inc. $109.73M $1.83 —
NTHI NEONC TECHNOLOGIES HOLDINGS, INC. $124.92M $4.33 —

News headlines (Yahoo Finance, 1h cache)

Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company
2026-11-18 00:02 · Yahoo
Spruce Biosciences Establishes Adrenyx Subsidiary to Develop CAH Treatment CRHX-101
2026-11-09 13:32 · Yahoo
Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
2026-11-09 13:00 · Yahoo
Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences
2026-11-09 12:00 · Yahoo
Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-02 21:05 · Yahoo
Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
2026-10-15 20:05 · Yahoo
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
2026-10-08 20:05 · Yahoo
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 20:05 · Yahoo
Spruce Biosciences stock gains after analyst backs regulatory progress
2026-08-27 12:09 · Yahoo
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
2026-08-24 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.